Skip to main content
logo
Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
38.70
+1.27 (3.39%)
Aug 4, 2026, 4:00 PM EDT - Market closed

Rigel Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
276.79294.28179.28116.88120.24149.24
Revenue Growth
3.31%64.15%53.38%-2.79%-19.43%37.39%
Gross Profit
252.95274.66160.63109.77118.49148.15
Operating Income
87.05125.4724.19-20.49-55.55-12.5
Net Income
321.91367.0217.49-25.09-58.57-17.91
Earnings Per Share
16.3219.480.99-1.44-3.44-1.10
EPS Growth
201.66%1867.68%----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
95.33154.9677.3256.9358.21124.97
Total Debt
39.9553.359.9760.5841.5530.57
Net Cash (Debt)
55.38101.6517.36-3.6516.6594.4
Net Cash Growth
16.99%485.69%---82.36%417.56%
Net Cash Per Share
2.835.400.98-0.210.985.54

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
79.3975.6631.47-5.74-73.765.88
Capital Expenditures
0.01--0.04--0.45-0.63
Free Cash Flow
79.475.6631.44-5.74-74.215.25
Free Cash Flow Growth
20.62%140.67%----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
91.39%93.33%89.60%93.92%98.55%99.27%
Operating Margin
31.45%42.63%13.49%-17.53%-46.20%-8.37%
Pretax Margin
30.92%41.40%10.24%-21.47%-48.71%-11.60%
Profit Margin
116.30%124.72%9.75%-21.47%-48.71%-12.00%
FCF Margin
28.69%25.71%17.53%-4.91%-61.72%3.52%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
2.352.2016.99---
Forward PE
10.0110.4917.39---
P/FCF Ratio
9.0210.379.48--86.60
PS Ratio
2.592.661.662.172.163.05